CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
Launched by GERMAN CANCER RESEARCH CENTER · Dec 7, 2022
Trial Information
Current as of January 16, 2025
Recruiting
Keywords
ClinConnect Summary
The CATCH trial is studying how to use genetic information to improve treatment for patients with metastatic breast cancer, which is breast cancer that has spread to other parts of the body. The main goal is to find specific markers in patients' tumors that can help doctors choose the best targeted therapies for their individual cases. This means that instead of a one-size-fits-all approach, treatments can be tailored to the unique characteristics of each patient's cancer.
To participate in the trial, you need to be at least 18 years old and diagnosed with advanced or metastatic breast cancer, regardless of the specific type or how many treatments you have already received. During the trial, doctors will collect samples from your cancer and blood to analyze them for genetic information. This will help identify potential treatments that might work best for you. The trial is currently recruiting participants, and it's important to know that if you decide to join, you will be contributing to valuable research that aims to improve future therapies for breast cancer patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Female and male breast cancer patients ≥ 18 or if the legal guardian has agreed to the respective informed consent form (ICF)
- • Patients with advanced or metastatic breast cancer (irrespective of clinical parameters such as TNM, subgroups, therapy lines)
- • Patients, who agreed to and were able to sign the informed consent form.
- Exclusion Criteria:
- • Early breast cancer
- • Inability to take a tissue bioptic sample due to reasons such as physical location of the lesion or health of the patient
- • Any physical or mental handicap or severe comorbidities that would hamper the adequate cooperation with the patient.
Trial Officials
Andreas Schneeweiss, MD
Principal Investigator
National Center for Tumor Diseases, Heidelberg
Peter Lichter, PhD
Principal Investigator
German Cancer Research Center
Verena Thewes, PhD
Principal Investigator
National Center for Tumor Diseases, Heidelberg
About German Cancer Research Center
The German Cancer Research Center (DKFZ) is a leading biomedical research institution dedicated to advancing cancer research and its application in clinical settings. Located in Heidelberg, DKFZ conducts innovative studies aimed at understanding the complexities of cancer biology, developing novel therapeutic strategies, and improving patient outcomes. As a prominent clinical trial sponsor, the center collaborates with national and international partners to facilitate cutting-edge research, translating scientific discoveries into effective treatments. With a commitment to excellence and a multidisciplinary approach, DKFZ plays a pivotal role in the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Erlangen, , Germany
Augsburg, , Germany
Tübingen, , Germany
Essen, , Germany
Berlin, , Germany
Ulm, , Germany
Würzburg, , Germany
Heidelberg, , Germany
Köln, , Germany
Dresden, , Germany
Regensburg, , Germany
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials